國家衛生研究院 NHRI:Item 3990099045/16413
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12340/13512 (91%)
造访人次 : 2260185      在线人数 : 246
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/16413


    题名: TCOG T3221 study: The registry of genetic alterations of Taiwan biliary tract cancer
    作者: Chiang, N;Hsu, C;Chen, J;Dai, M;Bai, L;Yen, C;Wang, T;Hsieh, Y;Lin, J;Chiu, T;Cheng, H;Yang, Y;Hsiao, C;Chen, L;Chen, M
    贡献者: National Institute of Cancer Research;Institute of Population Health Sciences
    摘要: Background :Recent advances in oncology drug development and next-generation sequencing (NGS)-based genomic profiling have greatly improved treatment precision for advanced biliary tract cancer (BTC). The current registration study (NCT05036486) was initiated to evaluate targetable genetic alterations in specific BTC groups in Taiwan. Methods: A total of 264 tumor tissues from 194 adenocarcinoma or adenosquamous carcinoma of intrahepatic cholangiocarcinoma (ICC), 38 extrahepatic cholangiocarcinoma (ECC), and 32 gallbladder cancer (GBC) were sequenced with a clinical-graded panel ACTOnco®+ encompassing 440 cancer-related genes. Therapeutic evidence of predictive biomarkers was categorized into levels 1-4 using the Memorial Sloan Kettering Precision Oncology Knowledge Base classification. Baseline characteristics, previous history, and subsequent treatment and outcomes were collected at six-month intervals until either expiration or five years following enrollment. Results: The most commonly altered genes in the entire cohort were TP53 (45%), KRAS (23%), CDKN2A (14%), ARID1A (13%), ERBB2(HER2, 11%), and BAP1 (7%). Therapeutic biomarkers with evidence levels 1-4 were identified in 58%, 58%, and 56% of patients with ICC, ECC, and GBC, respectively. Among the ICC group, 28.5% harbored level 1 biomarkers, including the IDH1R132C mutation (11.3%), FGFR2 fusions (10.5%), tumor mutation burden-high (TMB H, 5.7%), RET fusion (0.5%), and BRAFV600E mutation (0.5%), which occurred mutually exclusively. While level 1 therapeutic biomarkers are rarely found in non-ICC patients, such as 1 (2.6%) IDH1R132C mutation in ECC and 1 (3.1%) TMB-H in GBC, there is a notably higher prevalence of targetable HER2 alterations, including gene mutations and amplifications, in GBC (28.1%) compared to ICC (10.5%) and ECC (7.7%). Conclusions: Resutls from the extensive multi-center study in Taiwan on tissue NGS for specific BTC populations could become a benchmark for reimbursed diagnostic tests.
    日期: 2024-10
    關聯: Annals of Oncology. 2024 Oct;35(Suppl. 3):S1355.
    Link to: http://dx.doi.org/10.1016/j.annonc.2024.07.608
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001345709300196
    显示于类别:[陳立宗] 會議論文/會議摘要
    [姜乃榕] 會議論文/會議摘要
    [蕭金福] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI001345709300196.pdf86KbAdobe PDF18检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈